About

Mark J. Alvino became an Abeona director on March 26, 2021 and chairs the Compensation Committee and serves on the Audit Committee (which he chaired until April 2026); he had previously served on the Board from March 2006 to April 2020. He is the founder and Chairman of CircumferenceDx, a molecular diagnostics company he established in 2025, and has been President of Hudson Square Capital LLC since October 2014. From 2007 to 2013 he was Managing Director at Griffin Securities, and earlier he was Senior Vice President at Feinstein Kean Healthcare (an Ogilvy Public Relations Worldwide company) and Vice President of Investor Relations at Allen & Caron, Inc. He has also worked with Wall Street brokerages including Ladenburg Thalmann & Co. and Martin Simpson & Co.

Roles

Abeona Therapeutics Inc.
Director (Chair, Compensation Committee) · Current role
March 2021–present
CircumferenceDx
Founder and Chairman
2025 - present
Hudson Square Capital LLC
President
October 2014 - present
Griffin Securities
Managing Director
2007 - 2013
Feinstein Kean Healthcare (Ogilvy Public Relations Worldwide)
Senior Vice President
Allen & Caron, Inc.
Vice President of Investor Relations
Abeona Therapeutics Inc.
Director (prior service)
March 2006 - April 2020

Director Compensation

FY 2025
Fees earned or paid in cash
$85,000
ComponentAnnual board fee plus committee and committee-chair fees earned in 2025, paid quarterly
Stock awards
$200,000
ComponentRestricted stock award for 2025 Board service (36,101 shares granted January 31, 2025 at $5.54, ASC 718 grant-date fair value); vests one year after grant
Total
$285,000

Also at Abeona Therapeutics Inc.

Related

See how VectorShift works for your firm

Request Demo